• 1
    Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: ThomasED, BlumeKG, FormanSJ, eds. Hematopoietic cell transplantation. 2nd Ed. Cambridge , MA : Blackwell, 1999: 1218.
  • 2
    Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In: WingardJR, BowdenR, eds. Management of infection in oncology patients. Oxford , UK , 2004 (in press).
  • 3
    Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997;27: 572577.
  • 4
    Reed EC, Myerson D, Corey L, Myers JD. Allogeneic bone marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991;77: 195200.
  • 5
    Lau GKK, Lie AKW, Kwong YL et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000;96: 452458.
  • 6
    Locasciulli A, Alberti A, Bandini G et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995;86: 32363240.
  • 7
    Chen PM, Fan S, Liu CJ et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990;49: 708713.
  • 8
    Fan FS, Tzeng CH, Yeh HM, Chen PM. Reverse seroconversion of hepatitis B virus infections status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant 1992;10: 189191.
  • 9
    Rosendahl C, Bender-Goetze C, Deinhardt F, Kolb HJ, Hass R. Immunization against hepatitis B in BMT and leukemia patients. Exp Hematol 1985; 13 (Suppl 17):104110.
  • 10
    Mangioni S, Balduzzi A, Rivolta A et al. Long-term persistence of hematopoietic chimerism following sex-mismatched bone marrow transplantation. Bone Marrow Transplant 1997;20: 969973.DOI: 10.1038/sj.bmt.1701011
  • 11
    Locasciulli A, Testa M, Valsecchi MG et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the infectious disease working party of the European Blood and Marrow Transplantation Group. Transplantation 1999;68: 14861491.DOI: 10.1097/00007890-199911270-00010
  • 12
    Lau GK, Tsiang M, Hou J et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese patients: a viral dynamics study. Hepatology 2000;32: 394399.DOI: 10.1053/jhep.2000.9143
  • 13
    Lau GK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99: 23242330.
  • 14
    Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol 2003;31: 11821186.DOI: 10.1016/j.exphem.2003.09.008
  • 15
    Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003;32: 969978.DOI: 10.1038/sj.bmt.1704285
  • 16
    Rossi HA, Becker PS, Emmons RV et al. High-dose cyclophosphamide, BCNU and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma. Bone Marrow Transplt 2003;31: 441446.DOI: 10.1038/sj.bmt.1703874
  • 17
    Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36: 702709.DOI: 10.1053/jhep.2002.35068
  • 18
    McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118: 255267.
  • 19
    Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18: 295304.
  • 20
    Guidance on the microbiological safety of human organs, tissues and cells used in transplantation: Advisory committee on the Microbiological Safety of Blood and Tissues for Transplantation. United Kingdom Department of Health , August 2000.
  • 21
    National Marrow Donor Program: Eligibility guidelines for marrow and PBSC donation, July 2004.
  • 22
    Yeoh EK, Chang WK, Kwan JPW. Epidemiology of viral hepatitis B infection in Hong Kong. In: LamSK, LaiCL, YeohEK, eds. Viral hepatitis in the Western Pacific Region: vaccine and control. Singapore : World Scientific, 1984: 3344.
  • 23
    Zeldis JB, Mugishima H, Steinberg HN, Nir E, Gale RP. In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest 1986;78: 411417.
  • 24
    Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13: 359361.
  • 25
    Wagner D, Wagenbreth I, Stachan-Kunstyr R, Thoma H, Hemmerling AE, Flik J. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2 and S gene products. Clin Investig 1994;72: 350352.
  • 26
    Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125: 17421749.
  • 27
    Xunrong L, Au WY, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001;11: 287299.DOI: 10.1002/rmv.322
  • 28
    Schiff ER, Lai CL, Neuhaus P et al. Long-term safety and efficacy of adefovir dipivoxil (ADV) in the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine-resistant (LAM_R) hepatitis B virus. Hepatology 2004; 40 (Suppl 1): 660A.
  • 29
    Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000;32: 430432.DOI: 10.1053/jhep.2000.16181